171 related articles for article (PubMed ID: 38256106)
1. Exposure to Secondhand Smoke Extract Increases Cisplatin Resistance in Head and Neck Cancer Cells.
Sadhasivam B; Manyanga J; Ganapathy V; Acharya P; Bouharati C; Chinnaiyan M; Mehta T; Mathews B; Castles S; Rubenstein DA; Tackett AP; Zhao YD; Ramachandran I; Queimado L
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256106
[TBL] [Abstract][Full Text] [Related]
2. Cigarette Smoke Reduces the Efficacy of Cisplatin in Head and Neck Cancer Cells - Role of ABCG2.
Simon F; Schwenk-Zieger S; Becker S; Unger K; Gires O; Baumeister P
Anticancer Res; 2020 Mar; 40(3):1277-1284. PubMed ID: 32132024
[TBL] [Abstract][Full Text] [Related]
3. The effect of second hand smoke in patients with squamous cell carcinoma of the head and neck.
Idris S; Baqays A; Isaac A; Chau JKM; Calhoun KH; Seikaly H
J Otolaryngol Head Neck Surg; 2019 Jul; 48(1):33. PubMed ID: 31337433
[TBL] [Abstract][Full Text] [Related]
4. The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
Hagege A; Ambrosetti D; Boyer J; Bozec A; Doyen J; Chamorey E; He X; Bourget I; Rousset J; Saada E; Rastoin O; Parola J; Luciano F; Cao Y; Pagès G; Dufies M
Theranostics; 2021; 11(19):9571-9586. PubMed ID: 34646387
[No Abstract] [Full Text] [Related]
5. Targeting Wee1 kinase to suppress proliferation and survival of cisplatin-resistant head and neck squamous cell carcinoma.
Yang Z; Liao J; Lapidus RG; Fan X; Mehra R; Cullen KJ; Dan H
Cancer Chemother Pharmacol; 2022 Apr; 89(4):469-478. PubMed ID: 35212780
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma.
Routila J; Qiao X; Weltner J; Rantala JK; Carpén T; Hagström J; Mäkitie A; Leivo I; Ruuskanen M; Söderlund J; Rintala M; Hietanen S; Irjala H; Minn H; Westermarck J; Ventelä S
Oral Oncol; 2022 Apr; 127():105772. PubMed ID: 35245886
[TBL] [Abstract][Full Text] [Related]
7. TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via KEAP1/NRF2 signaling.
Xu T; Yang Y; Chen Z; Wang J; Wang X; Zheng Y; Wang C; Wang Y; Zhu Z; Ding X; Zhou J; Li G; Zhang H; Zhang W; Wu Y; Song X
J Exp Clin Cancer Res; 2023 Aug; 42(1):190. PubMed ID: 37525222
[TBL] [Abstract][Full Text] [Related]
8. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
[TBL] [Abstract][Full Text] [Related]
9. p38 Mitogen-activated protein kinase modulates cisplatin resistance in Head and Neck Squamous Cell Carcinoma cells.
Roy S; Roy S; Anuja K; Thakur S; Akhter Y; Padhi S; Banerjee B
Arch Oral Biol; 2021 Feb; 122():104981. PubMed ID: 33302041
[TBL] [Abstract][Full Text] [Related]
10. Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway.
Yang Z; Liao J; Carter-Cooper BA; Lapidus RG; Cullen KJ; Dan H
BMC Cancer; 2019 May; 19(1):485. PubMed ID: 31118072
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer.
Park SJ; Ye W; Xiao R; Silvin C; Padget M; Hodge JW; Van Waes C; Schmitt NC
Oral Oncol; 2019 Aug; 95():127-135. PubMed ID: 31345380
[TBL] [Abstract][Full Text] [Related]
12. New advances into cisplatin resistance in head and neck squamous carcinoma: Mechanisms and therapeutic aspects.
Hu H; Li B; Wang J; Tan Y; Xu M; Xu W; Lu H
Biomed Pharmacother; 2023 Jul; 163():114778. PubMed ID: 37137185
[TBL] [Abstract][Full Text] [Related]
13. 7-Epitaxol induces apoptosis in cisplatin-resistant head and neck squamous cell carcinoma via suppression of AKT and MAPK signalling.
Yang HJ; Velmurugan BK; Chen MK; Lin CC; Lo YS; Chuang YC; Ho HY; Hsieh MJ; Ko JL
J Cell Mol Med; 2022 Dec; 26(23):5807-5819. PubMed ID: 36308422
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin treatment induces a transient increase in tumorigenic potential associated with high interleukin-6 expression in head and neck squamous cell carcinoma.
Poth KJ; Guminski AD; Thomas GP; Leo PJ; Jabbar IA; Saunders NA
Mol Cancer Ther; 2010 Aug; 9(8):2430-9. PubMed ID: 20682658
[TBL] [Abstract][Full Text] [Related]
15. Targeting of FSP1 regulates iron homeostasis in drug-tolerant persister head and neck cancer cells via lipid-metabolism-driven ferroptosis.
Wu YC; Huang CS; Hsieh MS; Huang CM; Setiawan SA; Yeh CT; Kuo KT; Liu SC
Aging (Albany NY); 2024 Jan; 16(1):627-647. PubMed ID: 38206305
[TBL] [Abstract][Full Text] [Related]
16. Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma.
Hagege A; Saada-Bouzid E; Ambrosetti D; Rastoin O; Boyer J; He X; Rousset J; Montemagno C; Doyen J; Pedeutour F; Parola J; Bourget I; Luciano F; Bozec A; Cao Y; Pagès G; Dufies M
Cell Rep Med; 2022 Sep; 3(9):100659. PubMed ID: 36130479
[TBL] [Abstract][Full Text] [Related]
17. Ammonium tetrathiomolybdate enhances the antitumor effect of cisplatin via the suppression of ATPase copper transporting beta in head and neck squamous cell carcinoma.
Ryumon S; Okui T; Kunisada Y; Kishimoto K; Shimo T; Hasegawa K; Ibaragi S; Akiyama K; Thu Ha NT; Monsur Hassan NM; Sasaki A
Oncol Rep; 2019 Dec; 42(6):2611-2621. PubMed ID: 31638244
[TBL] [Abstract][Full Text] [Related]
18. Suppression of migration, invasion, and metastasis of cisplatin-resistant head and neck squamous cell carcinoma through IKKβ inhibition.
Liao J; Yang Z; Carter-Cooper B; Chang ET; Choi EY; Kallakury B; Liu X; Lapidus RG; Cullen KJ; Dan H
Clin Exp Metastasis; 2020 Apr; 37(2):283-292. PubMed ID: 32020377
[TBL] [Abstract][Full Text] [Related]
19. Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma.
Theile D; Gal Z; Warta R; Rigalli JP; Lahrmann B; Grabe N; Herold-Mende C; Dyckhoff G; Weiss J
Cancer Biol Ther; 2014 Apr; 15(4):436-42. PubMed ID: 24448417
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of IGF1R Expression Inhibits Growth and Enhances Cisplatin Sensitivity of Head and Neck Squamous Cell Carcinoma Cells In Vitro.
Khalil A; Jameson MJ
Horm Cancer; 2019 Feb; 10(1):11-23. PubMed ID: 30350263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
